Broncus Holding Corporation
2216.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$342.28M
Close$
$0.51
21.7% downside
Current Fair Value
21.7% downsideOvervalued by 21.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $342.28 Million |
|---|---|
| Enterprise Value | $321.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.04 |
| Beta | 1.11 |
| Outstanding Shares | 488,217,595 |
Return
| Return on Equity | -23.36% |
|---|---|
| Return on Assets | -22.16% |
| Return on Invested Capital | -31.04% |
Valuation & Multiples
| P/E Ratio | -2.21 |
|---|---|
| PEG | -54.18 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 40.84 |
| Enterprise Value to EBIT | -7.24 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Broncus Holding Corporation
195 employees
CEO: Hong Xu Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other i...